Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 30.5
(-4.39%)
SEK 30.5
(-4.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 109.88 Million SEK | 168.19% |
| 2022 | 40.97 Million SEK | 34.9% |
| 2021 | 30.37 Million SEK | -88.05% |
| 2020 | 254.13 Million SEK | 37.37% |
| 2019 | 185 Million SEK | 19.94% |
| 2018 | 154.25 Million SEK | 2.2% |
| 2017 | 150.92 Million SEK | 12.33% |
| 2016 | 134.35 Million SEK | 11.94% |
| 2015 | 120.02 Million SEK | 32.73% |
| 2014 | 90.42 Million SEK | -81.14% |
| 2013 | 479.54 Million SEK | 4.46% |
| 2012 | 459.08 Million SEK | 22.21% |
| 2011 | 375.66 Million SEK | 64.91% |
| 2010 | 227.8 Million SEK | -21.05% |
| 2009 | 288.54 Million SEK | -19.83% |
| 2008 | 359.92 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 145.69 Million SEK | 32.59% |
| 2024 Q3 | 68.42 Million SEK | -3.77% |
| 2024 Q2 | 134.02 Million SEK | -8.01% |
| 2023 Q3 | 111.53 Million SEK | 47.15% |
| 2023 FY | 109.88 Million SEK | 168.19% |
| 2023 Q1 | 55.35 Million SEK | 35.11% |
| 2023 Q2 | 75.79 Million SEK | 36.92% |
| 2023 Q4 | 109.88 Million SEK | -1.48% |
| 2022 Q3 | 36.92 Million SEK | -12.9% |
| 2022 FY | 40.97 Million SEK | 34.9% |
| 2022 Q1 | 42.85 Million SEK | 41.11% |
| 2022 Q4 | 40.97 Million SEK | 10.97% |
| 2022 Q2 | 42.39 Million SEK | -1.08% |
| 2021 Q2 | 254.33 Million SEK | -1.52% |
| 2021 Q3 | 13.21 Million SEK | -94.8% |
| 2021 Q4 | 30.37 Million SEK | 129.79% |
| 2021 FY | 30.37 Million SEK | -88.05% |
| 2021 Q1 | 258.27 Million SEK | 1.63% |
| 2020 Q2 | 241.58 Million SEK | 0.03% |
| 2020 Q1 | 241.52 Million SEK | 30.55% |
| 2020 Q3 | 250.1 Million SEK | 3.53% |
| 2020 Q4 | 254.13 Million SEK | 1.61% |
| 2020 FY | 254.13 Million SEK | 37.37% |
| 2019 Q2 | 239.18 Million SEK | 0.43% |
| 2019 Q1 | 238.15 Million SEK | 54.4% |
| 2019 Q3 | 217.21 Million SEK | -9.19% |
| 2019 Q4 | 185 Million SEK | -14.83% |
| 2019 FY | 185 Million SEK | 19.94% |
| 2018 Q3 | 150.42 Million SEK | -2.78% |
| 2018 Q2 | 154.72 Million SEK | -5.94% |
| 2018 Q1 | 164.49 Million SEK | 8.99% |
| 2018 FY | 154.25 Million SEK | 2.2% |
| 2018 Q4 | 154.25 Million SEK | 2.54% |
| 2017 Q4 | 150.92 Million SEK | 5.27% |
| 2017 Q2 | 149 Million SEK | -0.83% |
| 2017 Q1 | 150.24 Million SEK | 11.83% |
| 2017 FY | 150.92 Million SEK | 12.33% |
| 2017 Q3 | 143.36 Million SEK | -3.78% |
| 2016 FY | 134.35 Million SEK | 11.94% |
| 2016 Q4 | 134.35 Million SEK | 14.58% |
| 2016 Q3 | 117.26 Million SEK | -1.21% |
| 2016 Q2 | 118.7 Million SEK | 1.15% |
| 2016 Q1 | 117.35 Million SEK | -2.22% |
| 2015 FY | 120.02 Million SEK | 32.73% |
| 2015 Q4 | 120.02 Million SEK | 31.05% |
| 2015 Q3 | 91.58 Million SEK | 3.54% |
| 2015 Q2 | 88.45 Million SEK | -3.48% |
| 2015 Q1 | 91.64 Million SEK | 1.36% |
| 2014 Q1 | 470.57 Million SEK | -1.87% |
| 2014 FY | 90.42 Million SEK | -81.14% |
| 2014 Q4 | 90.42 Million SEK | 45.21% |
| 2014 Q3 | 62.27 Million SEK | 176.99% |
| 2014 Q2 | 22.48 Million SEK | -95.22% |
| 2013 Q3 | 447.57 Million SEK | -2.16% |
| 2013 Q4 | 479.54 Million SEK | 7.14% |
| 2013 FY | 479.54 Million SEK | 4.46% |
| 2013 Q1 | 451.61 Million SEK | -1.63% |
| 2013 Q2 | 457.43 Million SEK | 1.29% |
| 2012 Q3 | -56.53 Million SEK | -114.06% |
| 2012 Q2 | 402.14 Million SEK | 0.0% |
| 2012 FY | 459.08 Million SEK | 22.21% |
| 2012 Q4 | 459.08 Million SEK | 912.01% |
| 2011 Q4 | 375.66 Million SEK | 0.0% |
| 2011 FY | 375.66 Million SEK | 64.91% |
| 2010 FY | 227.8 Million SEK | -21.05% |
| 2009 FY | 288.54 Million SEK | -19.83% |
| 2008 FY | 359.92 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 412.618% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 91.044% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 91.044% |
| Arcoma AB | -1.12 Million SEK | 9841.312% |
| BICO Group AB (publ) | 927.9 Million SEK | 88.158% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 14.688% |
| CellaVision AB (publ) | -56.94 Million SEK | 292.972% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 838.603% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | 1399.577% |
| C-Rad AB (publ) | -127.6 Million SEK | 186.114% |
| Duearity AB (publ) | 10.23 Million SEK | -974.01% |
| Dignitana AB (publ) | 13.07 Million SEK | -740.269% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 308.505% |
| Getinge AB (publ) | 5.4 Billion SEK | 97.968% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 413.473% |
| Iconovo AB (publ) | -10.75 Million SEK | 1121.651% |
| Integrum AB (publ) | -10.47 Million SEK | 1148.839% |
| Luxbright AB (publ) | -13.83 Million SEK | 894.32% |
| Mentice AB (publ) | -49.56 Million SEK | 321.697% |
| OssDsign AB (publ) | -162.78 Million SEK | 167.5% |
| Paxman AB (publ) | -11.41 Million SEK | 1062.948% |
| Promimic AB (publ) | -50.32 Million SEK | 318.353% |
| Qlife Holding AB (publ) | 19.07 Million SEK | -476.203% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 502.145% |
| ScandiDos AB (publ) | -1.53 Million SEK | 7277.139% |
| Sectra AB (publ) | -772.85 Million SEK | 114.218% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 148.433% |
| Senzime AB (publ) | -139.54 Million SEK | 178.745% |
| SpectraCure AB (publ) | -50.23 Million SEK | 318.74% |
| Stille AB | -178.5 Million SEK | 161.557% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 91.052% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 151.191% |